Outcomes after resection of cholangiocellular carcinoma - 25/08/11
, Faye T Lee, R.N. a, Peter W Zimmer, M.D. a, John A Ryan, M.D. aAbstract |
Background |
Cholangiocellular carcinoma (CCC) is a rare primary liver malignancy that arises from intrahepatic bile duct canaliculi and presents as a liver mass. Our purpose is to report operative morbidity and mortality and to determine long-term survival after resection for CCC.
Methods |
Retrospective review of 31 consecutive patients who underwent resection during a 20-year period.
Results |
Thirty-day hospital mortality was 3%, and postoperative morbidity was 38%. Kaplan-Meier 5-year survival was 35%; mean survival was 37 months; absolute 5-year survival was 33%. Mean survival in stages I, II, IIIA, and IIIC were 57, 33, 26, and 14 months, respectively (P = 0.03 comparing I to >I). Recurrence occurred in 18 patients; 89% were in the liver. Carbohydrate antigen 19-9 >100 U/mL was found to be an indicator of poor prognosis (P = 0.009).
Conclusions |
Resection for CCC can be performed with acceptable morbidity and mortality rates and results in good survival and cure. Hepatic recurrence is common. Carbohydrate antigen 19-9 may be useful in determining prognosis.
Le texte complet de cet article est disponible en PDF.Keywords : Cholangiocellular carcinoma;, Liver mass;, Hepatic resection;, Intrahepatic cholangiocarcinoma
Plan
Vol 187 - N° 5
P. 612-617 - mai 2004 Retour au numéro
Article précédent
- Is splanchnic perfusion pressure more predictive of outcome than intragastric pressure in neonates with gastroschisis?
- Rebecca M McGuigan, Kenneth S Azarow
- Laparoscopic splenectomy for treatment of splenomegaly
- Leah Smith, Gregory Luna, Anders R Merg, M.Shane McNevin, Michael R Moore, Timothy W Bax
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?